Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

16.45 -0.66 (-3.89%)
Streaming Delayed Price Updated: 2:34 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 ↗
Janux's chief business officer unloaded 16.87% of his direct holdings in a routine insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Which stocks are moving on Tuesday? ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-12-02: top gainers and losers in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Navigating 10 Analyst Ratings For Janux Therapeutics ↗
 
Via Benzinga
News headline image
Why Janux Therapeutics Crushed the Market Today ↗
Via The Motley Fool
News headline image
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗
Janux shares plunged after the JANX007 trial update prompted widespread target cuts, even as retail traders framed the selloff as poised for a rebound. 
Via Stocktwits
News headline image
Which stocks are gapping on Tuesday? ↗
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'? ↗
Shares crashed Tuesday on what one analyst called an "overreaction" to the company's prostate cancer treatment update. 
Via Investor's Business Daily
News headline image
These stocks are moving in today's pre-market session ↗
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics ↗
 
Via Benzinga
News headline image
Navigating 5 Analyst Ratings For Janux Therapeutics ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Janux (JANX) R&D Soars Revenue Misses ↗
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Analyst Expectations For Janux Therapeutics's Future ↗
 
Via Benzinga
News headline image
The Top 5 Mid Cap Stocks Of 2024 ↗
These high-fliers are on the leading edge of innovation. 
Via Talk Markets
Topics Stocks / Equities
News headline image
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio? ↗
Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
S&P 500 Cools From Post-Election Record Highs ↗
The Dow Jones Industrial Average is down triple digits this afternoon, as traders unpack this morning's jobs data. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst ↗
Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients. 
Via Benzinga
News headline image
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients ↗
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels. 
Via Investor's Business Daily
News headline image
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing ↗
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
News headline image
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI ↗
Although fraught with risk, these biotech exposures bring enormous upside potential. 
Via Talk Markets
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.